TP53 and in situ carcinoma: Shariat and colleagues [70] reported a frequent association between p53 and p21 positivity in a cohort of CIS cases, the latter being is a cyclin-dependent kinase inhibitor involved in cell cycle regulation; however, only p21 expression was associated with risk of progression to invasive carcinoma.